CAS 1401812-88-1

Immunoglobulin G1, anti-(human phosphate-sodium cotransporter NaPi3b) (human-Mus musculus monoclonal DNIB0600A heavy chain), disulfide with human-Mus musculus monoclonal DNIB0600A light chain, dimer, tetrakis(thioether) with N-[[[4-[[N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide

Description:

Immunoglobulin G1 (IgG1) is a type of antibody that plays a crucial role in the immune response, specifically targeting antigens such as proteins or pathogens. The substance described is a monoclonal antibody, specifically engineered to bind to the human phosphate-sodium cotransporter NaPi3b, which is involved in phosphate transport in cells. This particular IgG1 is characterized by its dimeric structure, formed by the heavy and light chains linked via disulfide bonds, enhancing its stability and functionality. The presence of tetrakis(thioether) indicates that the molecule has multiple sulfur-containing groups, which may contribute to its binding affinity and specificity. The complex nomenclature suggests a highly modified structure, likely designed for improved therapeutic efficacy or targeting precision. The CAS number 1401812-88-1 uniquely identifies this compound, facilitating its recognition in scientific literature and regulatory databases. Overall, this substance exemplifies the intricate design of monoclonal antibodies for targeted therapeutic applications in biomedical research and treatment.

Formula: Unspecified

Synonyms:

• Anti-NaPi3b vedotin
• DNIB 0600A
• Lifastuzumab vedotin
• Immunoglobulin G1, anti-(human phosphate-sodium cotransporter NaPi3b) (human-Mus musculus monoclonal DNIB0600A heavy chain), disulfide with human-Mus musculus monoclonal DNIB0600A light chain, dimer, tetrakis(thioether) with N-[[[4-[[N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide

Lifastuzumab vedotin

CAS: 1401812-88-1

Lifastuzumab vedotin (DNIB0600A), an antibody-drug conjugate (ADC), consists of a humanized IgG1 monoclonal antibody targeting NaPi2b (MNIB2126A) linked to the potent antimitotic agent monomethyl auristatin E (MMAE), which disrupts cell division by inhibiting tubulin polymerization. This compound shows promise for research in non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) [1].

Color and Shape: Liquid

Ref: TM-T9901A-025

Lifastuzumab

CAS: 1401812-88-1

A human recombinant monoclonal antibody targeting SLC34A2.

Ref: 3D-CLA1342